Please assess the completion status of the following clinical trial:

Trial Title: Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hepatocellular carcinoma with liver-dominant disease. Diagnosis may be made by histo- or cyto-pathology, or by clinical and imaging criteria.~* The cancer is unresectable.~* All patients must be off all chemotherapeutic regimens for 30 days prior to and 30 days after TheraSphere treatment.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~* Age 18 years or older.~* Able to understand informed consent.~Exclusion Criteria:~* Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs on either:~  * single TheraSphere administration; or~ * cumulative delivery of radiation to the lungs greater than 50 Gy over multiple treatments.~* Evidence of any detectable Tc-99m macroaggregated albumin flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow.~* Previous radiation therapy to the lungs and/or to the upper abdomen~* Pregnancy~* Symptomatic lung disease.~* Significant extrahepatic disease representing an imminent life-threatening outcome.~* Active uncontrolled infection~* Any pre-treatment laboratory findings within 30 days of treatment demonstrating:~  * Aspartate or alanine aminotransferase level greater than 5 times upper normal limit.~ * Serum bilirubin greater than 2 mg/dl~ * Infiltrative tumor on imaging~ * Tumor volume greater than 70% of liver volume~ * Tumor volume greater than 50% of liver volume and serum albumin level less than 3 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Yttrium-90 liver radioembolization (Type: EXPERIMENTAL): Patients who receive liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere)

Based on this trial design, predict the completion outcome and termination type (if applicable).